Fantine Giap
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fantine Giap has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Fumiko Chino
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
3 shared publications Amir Owrangi
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX
1 shared publication- Andrea L. Russo
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
1 shared publication Andrzej Niemierko
Department of Radiation Oncology Biostatistics, Massachusetts General Hospital, Boston, MA
1 shared publicationAnne B. Giersch
Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
1 shared publication- Arjun Gupta
City of Hope Cancer Center, Phoenix, AZ
1 shared publication
Latest Publications
- 18 November 2025
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 64 (11) , e70094
“Benign” Metastasizing Fibrous Histiocytoma Harboring PRKCD Gene Fusions With Malignant Clinical Course
Dermatofibroma/fibrous histiocytoma is a common tumor of the dermis, composed of myofibroblasts, dendrocytes, and macrophages with characteristic entrapment of dermal collagen fibers at the periphery of the tumor. Various subtypes of dermatofibroma, including cellular, aneurysmal, and atypical dermatofibroma, are associated with an increased risk of recurrence, especially with incomplete excision. Two cases of benign fibrous histiocytoma with recurrence and metastasis are described. Patient 1 had a cellular fibrous histiocytoma with KIRREL1 :: PRKCD fusion presenting as a superficial and deep soft tissue mass involving the scapula and lateral clavicle. Patient 1 subsequently developed metastasis to the chest wall and thigh. Patient 2 had a recurrent aneurysmal fibrous histiocytoma with LAMTOR1 :: PRKCD fusion presenting as a large shoulder mass with invasion of the clavicle and lymph node metastasis. Patient 2 developed rapid local recurrence and PET‐avid pulmonary nodules, radiologically consistent with metastasis. Fibrous histiocytoma is typically a morphologically benign neoplasm that only rarely exhibits clinically aggressive behavior with multiple recurrences and metastases. Although uncommon, recognition of this entity is important so that pathologists and sarcoma oncologists can ensure accurate diagnosis, multidisciplinary management, and appropriate clinical surveillance. In addition, complex chromosomal abnormalities may serve as useful indicators of fibrous histiocytoma with the risk of aggressive clinical behavior.
- 18 November 2025
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 64 (11) , e70094
“Benign” Metastasizing Fibrous Histiocytoma Harboring PRKCD Gene Fusions With Malignant Clinical Course
Dermatofibroma/fibrous histiocytoma is a common tumor of the dermis, composed of myofibroblasts, dendrocytes, and macrophages with characteristic entrapment of dermal collagen fibers at the periphery of the tumor. Various subtypes of dermatofibroma, including cellular, aneurysmal, and atypical dermatofibroma, are associated with an increased risk of recurrence, especially with incomplete excision. Two cases of benign fibrous histiocytoma with recurrence and metastasis are described. Patient 1 had a cellular fibrous histiocytoma with KIRREL1 :: PRKCD fusion presenting as a superficial and deep soft tissue mass involving the scapula and lateral clavicle. Patient 1 subsequently developed metastasis to the chest wall and thigh. Patient 2 had a recurrent aneurysmal fibrous histiocytoma with LAMTOR1 :: PRKCD fusion presenting as a large shoulder mass with invasion of the clavicle and lymph node metastasis. Patient 2 developed rapid local recurrence and PET‐avid pulmonary nodules, radiologically consistent with metastasis. Fibrous histiocytoma is typically a morphologically benign neoplasm that only rarely exhibits clinically aggressive behavior with multiple recurrences and metastases. Although uncommon, recognition of this entity is important so that pathologists and sarcoma oncologists can ensure accurate diagnosis, multidisciplinary management, and appropriate clinical surveillance. In addition, complex chromosomal abnormalities may serve as useful indicators of fibrous histiocytoma with the risk of aggressive clinical behavior.
- 23 May 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , 510-514
Understanding anxiety in patients receiving vaginal brachytherapy for low-grade early-stage endometrial cancer
- 23 May 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , 510-514
Understanding anxiety in patients receiving vaginal brachytherapy for low-grade early-stage endometrial cancer
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 249
Perceptions and needs of pet owners with cancer: Results from a national survey from the CancerCare Pet Assistance and Wellness (PAW) program.
249 Background: Many patients diagnosed with cancer own pets, yet information addressing pet care during cancer treatment is both rare and inconsistent in content. The resultant gap of knowledge and need for resources is not well understood. Cancer Care (a national non-profit providing emotional and practical support services) created a survey to assess pet owner perspectives with the goal of implementing patient-informed solutions. Methods: A mixed methods approach was utilized including an original 11-question online survey sent to 8434 patients with cancer known to own pets in August 2021. The survey asked about pets in the home and pet care knowledge and needs. A focus group of 10 patients was selected from the 84 who volunteered and included 6 females, 4 males, age range 41-68, from a variety of race/ethnicities. This research was funded through a grant from Amie’s Place Foundation. Results: 328 responses were collected in the 10 days of survey administration. The most common pets in the home were dogs (77%) and cats (45%) with a minority (2-5%) reporting other pets. The vast majority (98%) reported that their pets were extremely or very important in their recovery from cancer treatment. Prior to cancer diagnosis, most were involved in feeding (89%), taking pets to the veterinarian (80%), grooming (70%), walking (68%), administering pet meds (56%), and cleaning soiled pet items (47%). After cancer diagnosis, many relied on help from their spouse/partner (41%), children (33%), friends (14%); 15% noted that they didn’t have anyone else to help with their pets. Over half (55%) had safety concerns regarding pet care since their cancer diagnosis. Of the 77% with questions about caring for their pet, the 3 most common concerns were: how to care for their pets when feeling unwell (58%), infections from their pets (47%), and impact of their cancer treatment on pets (36%). Places from which respondents wanted information included CancerCare.org (66%), their veterinarian’s office (32%), or the treating cancer center (25%). Information was best received online (56%), or via printed materials (46%), and downloadable fact sheets (24%). The focus group findings confirmed the emotional support and companionship that pets provided (“ When I was at my lowest point, my dog kept me up and going.”) but highlighted the need for additional assistance for pet care needs and information from their care team (“ Cancer patients don’t have a clear direction on where to go for resources on how to take care of your pet.”). Conclusions: While almost all surveyed pet owners with cancer highly value the emotional support their pet provides and state it helped them recover from cancer treatment, there is a clear need for improved information dissemination regarding patient and pet safety during the patient’s cancer treatment. Accurate and accessible information would benefit patients with cancer and fill an unmet need.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 249
Perceptions and needs of pet owners with cancer: Results from a national survey from the CancerCare Pet Assistance and Wellness (PAW) program.
249 Background: Many patients diagnosed with cancer own pets, yet information addressing pet care during cancer treatment is both rare and inconsistent in content. The resultant gap of knowledge and need for resources is not well understood. Cancer Care (a national non-profit providing emotional and practical support services) created a survey to assess pet owner perspectives with the goal of implementing patient-informed solutions. Methods: A mixed methods approach was utilized including an original 11-question online survey sent to 8434 patients with cancer known to own pets in August 2021. The survey asked about pets in the home and pet care knowledge and needs. A focus group of 10 patients was selected from the 84 who volunteered and included 6 females, 4 males, age range 41-68, from a variety of race/ethnicities. This research was funded through a grant from Amie’s Place Foundation. Results: 328 responses were collected in the 10 days of survey administration. The most common pets in the home were dogs (77%) and cats (45%) with a minority (2-5%) reporting other pets. The vast majority (98%) reported that their pets were extremely or very important in their recovery from cancer treatment. Prior to cancer diagnosis, most were involved in feeding (89%), taking pets to the veterinarian (80%), grooming (70%), walking (68%), administering pet meds (56%), and cleaning soiled pet items (47%). After cancer diagnosis, many relied on help from their spouse/partner (41%), children (33%), friends (14%); 15% noted that they didn’t have anyone else to help with their pets. Over half (55%) had safety concerns regarding pet care since their cancer diagnosis. Of the 77% with questions about caring for their pet, the 3 most common concerns were: how to care for their pets when feeling unwell (58%), infections from their pets (47%), and impact of their cancer treatment on pets (36%). Places from which respondents wanted information included CancerCare.org (66%), their veterinarian’s office (32%), or the treating cancer center (25%). Information was best received online (56%), or via printed materials (46%), and downloadable fact sheets (24%). The focus group findings confirmed the emotional support and companionship that pets provided (“ When I was at my lowest point, my dog kept me up and going.”) but highlighted the need for additional assistance for pet care needs and information from their care team (“ Cancer patients don’t have a clear direction on where to go for resources on how to take care of your pet.”). Conclusions: While almost all surveyed pet owners with cancer highly value the emotional support their pet provides and state it helped them recover from cancer treatment, there is a clear need for improved information dissemination regarding patient and pet safety during the patient’s cancer treatment. Accurate and accessible information would benefit patients with cancer and fill an unmet need.
- 12 May 2022
- Published by Wiley
- p. 495-520
Particle Therapy for Non‐CNS Pediatric Malignancies
- 1 April 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (4) , 310-311
Systems-Level Changes to Address Financial Toxicity in Cancer Care
- 1 April 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (4) , 310-311
Systems-Level Changes to Address Financial Toxicity in Cancer Care
- 30 November 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (2) , 106-108
What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom Relief
- 30 November 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (2) , 106-108
What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom Relief
- 1 January 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (1) , 136-145
Predicting which patients may benefit from the hybrid intracavitary+interstitial needle (IC/IS) applicator for advanced cervical cancer: A dosimetric comparison and toxicity benefit analysis
- 1 January 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (1) , 136-145
Predicting which patients may benefit from the hybrid intracavitary+interstitial needle (IC/IS) applicator for advanced cervical cancer: A dosimetric comparison and toxicity benefit analysis
- Open Access
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , E149
Intensity Modulated Proton Therapy for the Retreatment of Rectal and Anal Cancer
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , E149
Open AccessIntensity Modulated Proton Therapy for the Retreatment of Rectal and Anal Cancer
- Open Access
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (2) , E509
Impact of Baseline Cachexia in Non-Small Cell Lung Cancer on Radiation Therapy Utilization and Survival
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (2) , E509
Open AccessImpact of Baseline Cachexia in Non-Small Cell Lung Cancer on Radiation Therapy Utilization and Survival